Glucagon-Like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Experienced Patients with Type 2 Diabetes Mellitus: A Preference Study in Germany and the United Kingdom. - Wikidata - wikimedia - TriplyDB

Glucagon-Like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Experienced Patients with Type 2 Diabetes Mellitus: A Preference Study in Germany and the United Kingdom.

Glucagon-Like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Experienced Patients with Type 2 Diabetes Mellitus: A Preference Study in Germany and the United Kingdom.

http://www.wikidata.org/entity/Q37737463

about

Reproducibility and Validity of a Questionnaire Measuring Treatment Burden on Patients with Type 2 Diabetes: Diabetic Treatment Burden Questionnaire (DTBQ).

P2860

Q55041856-DE2B20A7-48E1-40C7-A697-93FCC8160D61

P2860

Glucagon-Like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Experienced Patients with Type 2 Diabetes Mellitus: A Preference Study in Germany and the United Kingdom.

http://www.wikidata.org/entity/Q37737463

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 24 February 2017

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Glucagon-Like Peptide-1 Recept ...... ermany and the United Kingdom.

@en

Glucagon-Like Peptide-1 Recept ...... ermany and the United Kingdom.

@nl

type

label

Glucagon-Like Peptide-1 Recept ...... ermany and the United Kingdom.

@en

Glucagon-Like Peptide-1 Recept ...... ermany and the United Kingdom.

@nl

prefLabel

Glucagon-Like Peptide-1 Recept ...... ermany and the United Kingdom.

@en

Glucagon-Like Peptide-1 Recept ...... ermany and the United Kingdom.

@nl

P1433

Q37737463-97B97FED-779D-4837-8D19-CAAD5CAAF76F

P1476

Q37737463-A556FED5-BE16-4F1A-A71A-501B71162AAC

P2093

Q37737463-07ACFAE7-2BB5-4F22-853B-5630870A32EB

Q37737463-0F3B7665-FC27-443D-88D5-8E0A2C87CA15

Q37737463-1DDA393C-C39B-4E8F-B76E-F24858272E18

Q37737463-335352C8-53DD-494F-9659-932621319332

Q37737463-75CEDFFD-641D-461D-B3A8-1F30F94C3955

Q37737463-79EAE6FB-4FD2-4E61-A03D-4A331EF1701B

Q37737463-886ADD8E-8524-43B1-8848-1380207B217D

Q37737463-C80D41A4-CE0A-49B7-AC2C-FC51E07C134C

P2860

Q37737463-03D032DA-B1A4-4F84-8453-D7E888A2CB8E

Q37737463-0E56725E-E63E-4B1F-9071-5BCA0D876671

Q37737463-0F03067C-00F4-415E-84E8-5D513454EC4B

Q37737463-11296401-49B4-4024-A00E-2FF0727B2519

Q37737463-178B1890-BA5A-486A-ABF7-AF09F623E797

Q37737463-24849F04-3069-4D5B-8925-32B52489BE47

Q37737463-34608766-9E53-4D04-A052-76AE1CB5EF12

Q37737463-3AD10037-54EA-4F1B-A8B5-109FFC6062F7

Q37737463-3CD29D31-3419-439A-AAFC-99F25B5D82D2

Q37737463-402FB529-12D4-408D-8046-CBEB2D865A38

P2888

Q37737463-4DF473C6-3978-4D93-817B-3E1869FF61DA

P304

Q37737463-A7488AA2-4C15-45C8-82DB-7F7F1C9D806C

P31

Q37737463-3CFE0F8C-7A83-4A58-BCC6-04388CC7101B

P356

Q37737463-C4205D04-E65D-4663-8DA5-B9946C80DC3E

P433

Q37737463-B40D98FF-B9FC-4366-8869-52187D53D53C

P478

Q37737463-95C44560-1E3D-4D29-AE7E-0043FCD10D60

P577

Q37737463-E162BADE-52B1-4BFF-9C38-D83B0BD565E1

P698

Q37737463-41B4463A-5A84-45C7-A440-1FA2D7DE53CF

P921

Q37737463-7C96EA62-DD35-481B-8593-789FE0F165D5

Q37737463-C4153C02-CE68-41AF-9987-9067C85AE837

P932

Q37737463-397AC4E6-A116-430B-8546-5D4D93BF082D

P356

S13300-017-0237-8

P1433

Diabetes Therapy

P1476

Glucagon-Like Peptide-1 Recept ...... ermany and the United Kingdom.

@en

P2093

Alka Shaunik

http://www.w3.org/2001/XMLSchema#string

Beverly Romero

http://www.w3.org/2001/XMLSchema#string

Cynthia Alvarez

http://www.w3.org/2001/XMLSchema#string

Emuella Flood

http://www.w3.org/2001/XMLSchema#string

Lei Qin

http://www.w3.org/2001/XMLSchema#string

Marie de la Cruz

http://www.w3.org/2001/XMLSchema#string

Stephanie Chen

http://www.w3.org/2001/XMLSchema#string

Susan Grandy

http://www.w3.org/2001/XMLSchema#string

P2860

Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors

GLP-1 receptor agonists: a review of head-to-head clinical studies

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants

Prevalence, incidence and concomitant co-morbidities of type 2 diabetes mellitus in South Western Germany--a retrospective cohort and case control study in claims data of a large statutory health insurance

Prevalence and incidence of diabetes in Stockholm County 1990-2010.

Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.

Use of discrete choice experiments to elicit preferences.

P2888

s13300-017-0237-8

P304

335-353

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13300-017-0237-8

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2017-02-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28236271

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

5380499

http://www.w3.org/2001/XMLSchema#string